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activity brief

Evaluating a Depression Treatment
Program on HIV Care and Mental Health
Outcomes in Malawi

The potential for depression treatment to improve
HIV care outcomes has received little attention
in the region, in part because of the very limited
mental health infrastructure in many countries.
Malawi’s Ministry of Health is working to build
mental health capacity through task-sharing
approaches, including training primary care
providers and outreach workers in mental health
screening and counseling.
Project SOAR is working with the Ministry of Health
to implement and evaluate the integration of a
depression management program into HIV care
in Malawi—a country in which nearly a quarter
of people initiating ART are lost to care within
the first 12 months.4 The project combines two
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Among people initiating antiretroviral therapy
(ART), those with depression are a large and
especially vulnerable population. Depression
affects 18–30 percent of patients receiving HIV
care in Africa1 and is an important barrier to early
ART retention.2,3

This study will provide critical evidence on the feasibility,
effectiveness, and cost-effectiveness of an integrated
depression treatment model. Such evidence has
implications not only for Malawi, but for other
sub-Saharan countries as well.

depression treatment models—algorithm-based
medication management and problem-solving
therapy—into a single program that is offered
at two HIV clinics in Lilongwe to patients newly
initiating antiretroviral treatment and who have
depressive symptoms.
This study will provide critical evidence on the
feasibility, effectiveness, and cost-effectiveness
of an integrated depression treatment model for
improving retention in and adherence to HIV care.
Such evidence has implications not only for the
applicability of the model in Malawi but for other
countries in sub-Saharan Africa as well.

OUR RESEARCH

The study employs a pre-post design over a
15-month period. There is an initial observation
period at both clinics during which HIV and mental
health outcomes are being measured among
clients initiating ART and receiving standard care.
Subsequently, the clinics will integrate the mental

health treatment program at different times. The
study team will continue to measure HIV and
mental health outcomes among clients initiating
ART together with the combined mental health
treatment program.

What are the study’s outcome
indicators?
HIV
 Proportion of patients keeping all HIV care
appointments required to maintain their ART
supply through the first six months on ART

We expect to abstract depression screening
data across the two clinics for approximately
1,830 adult patients newly initiating ART. We
also will abstract further treatment and outcome
data before and after the intervention for those
patients who screen positive for mild, moderate,
or severe depression. We will compare retention
in HIV care, viral suppression, and depression
response and remission among patients receiving
the combined program compared to those
receiving usual care.

 Proportion of patients with a HIV RNA viral
load of <1,000 copies/mL approximately six
months (+/- six weeks) after starting ART
Mental health
 Proportion of patients with remission of
depressive symptoms at six months
 Proportion of patients with a decrease of
50 percent or more in depressive symptoms
from baseline to six months

RESEARCH UTILIZATION

Cost and cost-effectiveness

The research team is engaging a range of
stakeholders, including health facility staff and
Ministry of Health officials, over the course of the
study to foster research utilization. For example,
select stakeholders will present preliminary
findings at a data interpretation workshop
and lead discussions on their implications for
programs and policy. Subsequently, the research
team, Ministry officials, and facility staff will
develop a data use plan that will help guide the
local dissemination agenda and target audiences.
In addition to presentations at local and regional
conferences, all involved clinics will receive a
formal presentation regarding program outcomes
and proposed next steps. In coordination with
our stakeholders and partners in the Ministry of
Health, we will also develop presentations that
are geared specifically to local clinics that were
not involved in the program, transferring relevant
information and “lessons learned” from on-theground healthcare workers. Finally, through our
identified Ministry stakeholders, we will present
our results to the Ministry of Health HIV care and
treatment group and the National Health Sciences
research committee to facilitate discussion
regarding policy implications of our findings.
Project SOAR is a five-year (September 2014–September 2019) cooperative
agreement funded by the President’s Emergency Plan for AIDS Relief
and the U. S. Agency for International Development (Agreement No. AIDOAA-A-14-00060). SOAR is able to accept funding from all USAID accounts.
Population Council leads the Project SOAR consortium in collaboration with
Avenir Health, Elizabeth Glaser Pediatric AIDS Foundation, the Johns Hopkins
University, Palladium, and The University of North Carolina at Chapel Hill.

 Expense associated with delivering the
depression treatment program per patient
and per clinic
 Cost per additional case of viral suppression
achieved
 Cost per additional case of depression
remission achieved
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